Aduro BioTech (NASDAQ:ADRO) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.03, Fidelity Earnings reports. The company had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $4.55 million. Aduro BioTech had a negative return on equity of 68.69% and a negative net margin of 624.51%.
NASDAQ:ADRO opened at $1.18 on Friday. The stock has a market cap of $91.36 million, a P/E ratio of -1.02 and a beta of 1.48. The company has a current ratio of 8.45, a quick ratio of 8.45 and a debt-to-equity ratio of 0.32. The stock’s 50-day moving average is $1.05 and its 200-day moving average is $1.79. Aduro BioTech has a 1-year low of $0.90 and a 1-year high of $4.59.
In other news, CEO Stephen T. Isaacs sold 31,098 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $1.31, for a total transaction of $40,738.38. Following the sale, the chief executive officer now directly owns 295,926 shares in the company, valued at $387,663.06. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have sold 52,185 shares of company stock worth $68,362. Company insiders own 5.20% of the company’s stock.
About Aduro BioTech
Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.
Featured Story: Limitations to arbitrage trading
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.